跳至主要内容
临床试验/DRKS00022786
DRKS00022786进行中(未招募)不适用

Assessment of the Safety and Performance of the HARPOON™ Beating Heart Mitral Valve Repair System; a Multi-center Post-market Study (ASCEND) - ASCEND

Harpoon Medical, an indirect-wholly owned subsidiary of Edwards Lifesciences Corporation, Edwards Lifesciences,0 个研究点目标入组 42 人开始时间: 2020年10月5日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Subject is = 18 years old
  • 2. Presence of severe MR as read on a transthoracic echocardiographic study
  • 3. Mitral leaflet coaptation surface is sufficient to reduce mitral regurgitation without undue leaflet tension approximate leaflet to gap ratio of 2:1) based on the judgment of the patient eligibility committee and the operating surgeon
  • 4. Degenerative mitral valve disease with mid-segment P2 prolapse
  • 5. Patient is able to sign informed consent and able to return for follow-up and is capable of participating in all testing associated with this clinical investigation

排除标准

  • 1. Patient is of the age where further growth is expected
  • 2. Active endocarditis
  • 3. Left ventricular or left atrial appendage thrombus
  • 4. Severe mitral annular and/or leaflet calcification
  • 5. Cannot tolerate procedural anticoagulation or post-procedure antiplatelet regimen
  • 6. Mitral stenosis
  • 7. Functional Mitral Valve disease
  • 8. Previous mitral valve replacement surgery
  • 9. Fragile or thinning apex
  • 10. Contraindications to transoesophageal echocardiography (atlantoaxial disease, severe generalized cervical arthritis, upper gastrointestinal bleeding, significant dysphagia and odynophagia, has received extensive radiation to the mediastinum)
  • 11. Patient is pregnant or lactating

研究者

发起方
Harpoon Medical, an indirect-wholly owned subsidiary of Edwards Lifesciences Corporation, Edwards Lifesciences,

相似试验